TMEM119 as a specific marker of microglia reaction in traumatic brain injury in postmortem examination.
Adolescent
Adult
Aged
Aged, 80 and over
Autopsy
Biomarkers
Brain Injuries, Traumatic
/ pathology
Cerebellum
/ cytology
Child
Child, Preschool
Female
Forensic Pathology
Humans
Immunohistochemistry
Male
Membrane Glycoproteins
Membrane Proteins
Microglia
/ metabolism
Middle Aged
Pons
/ cytology
Receptors, CCR2
Receptors, Immunologic
White Matter
/ cytology
Young Adult
Biomarker
Cerebrospinal fluid
Forensic neuropathology
Forensic neurotraumatology
Immunocytochemistry
Immunohistochemistry
Journal
International journal of legal medicine
ISSN: 1437-1596
Titre abrégé: Int J Legal Med
Pays: Germany
ID NLM: 9101456
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
17
04
2020
accepted:
23
07
2020
pubmed:
29
7
2020
medline:
13
7
2021
entrez:
29
7
2020
Statut:
ppublish
Résumé
The aim of the present study was a refined analysis of neuroinflammation including TMEM119 as a useful microglia-specific marker in forensic assessments of traumatic causes of death, e.g., traumatic brain injury (TBI). Human brain tissue samples were obtained from autopsies and divided into cases with lethal TBI (n = 25) and subdivided into three groups according to their trauma survival time and compared with an age-, gender-, and postmortem interval-matched cohort of sudden cardiovascular fatalities as controls (n = 23). Brain tissue samples next to cortex contusions and surrounding white matter as well as samples of the ipsilateral uninjured brain stem and cerebellum were collected and stained immunohistochemically with antibodies against TMEM119, CD206, and CCR2. We could document the highest number of TMEM119-positive cells in acute TBI death with highly significant differences to the control numbers. CCR2-positive monocytes showed a significantly higher cell count in the cortex samples of TBI cases than in the controls with an increasing number of immunopositive cells over time. The number of CD206-positive M2 microglial cells increased survival time-dependent. After 3 days of survival, the cell number increased significantly in all four regions investigated compared with controls. In sum, we validate a specific and robustly expressed as well as fast reacting microglia marker, TMEM119, which distinguishes microglia from resident and infiltrating macrophages and thus offers a great potential for the estimation of the minimum survival time after TBI.
Identifiants
pubmed: 32719959
doi: 10.1007/s00414-020-02384-z
pii: 10.1007/s00414-020-02384-z
pmc: PMC7578160
doi:
Substances chimiques
Biomarkers
0
CCR2 protein, human
0
MRC1 protein, human
0
Membrane Glycoproteins
0
Membrane Proteins
0
Receptors, CCR2
0
Receptors, Immunologic
0
Tmem119 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2167-2176Références
Br J Pharmacol. 2016 Feb;173(4):649-65
pubmed: 25800044
Expert Rev Mol Diagn. 2018 Feb;18(2):165-180
pubmed: 29338452
Brain Inj. 2017;31(9):1195-1203
pubmed: 28981341
Neuropathol Appl Neurobiol. 2011 Feb;37(2):118-34
pubmed: 20946118
Int J Legal Med. 2018 Jul;132(4):1103-1109
pubmed: 29299666
Pharmacol Ther. 2016 Jul;163:82-93
pubmed: 27101921
Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):E1738-46
pubmed: 26884166
CNS Neurosci Ther. 2013 Aug;19(8):556-65
pubmed: 23710877
Science. 2007 Aug 3;317(5838):666-70
pubmed: 17673663
Int J Legal Med. 2007 May;121(3):175-83
pubmed: 17031692
Sci Rep. 2019 Aug 15;9(1):11771
pubmed: 31417126
Neural Plast. 2017;2017:5405104
pubmed: 28255460
Science. 2013 Jan 11;339(6116):156-61
pubmed: 23307732
BMC Cancer. 2009 Aug 22;9:292
pubmed: 19698134
Neuroreport. 1997 Jan 20;8(2):395-8
pubmed: 9080414
Biol Psychiatry. 2014 Oct 1;76(7):575-84
pubmed: 24289885
Nat Rev Neurol. 2015 Jan;11(1):56-64
pubmed: 25385337
Glia. 2005 Feb;49(3):375-84
pubmed: 15538754
eNeuro. 2016 Dec 21;3(6):
pubmed: 28032118
Nat Neurosci. 2013 Sep;16(9):1211-1218
pubmed: 23872599
J Neurotrauma. 2016 Oct 1;33(19):1732-1750
pubmed: 26486881
Int J Legal Med. 2019 Jul;133(4):1141-1146
pubmed: 30927078
Neuroscience. 2006;138(4):1215-23
pubmed: 16431029
Forensic Sci Int. 2017 Nov;280:1-7
pubmed: 28942078
Nat Neurosci. 2013 Dec;16(12):1896-905
pubmed: 24162652
Front Aging Neurosci. 2017 Jun 28;9:208
pubmed: 28701948
Clin Dev Immunol. 2013;2013:285246
pubmed: 23983766
J Forensic Leg Med. 2018 Apr;55:65-73
pubmed: 29471249
Neuropathology. 2016 Feb;36(1):39-49
pubmed: 26250788
Acta Neuropathol. 1999 May;97(5):491-4
pubmed: 10334486
Int J Legal Med. 2000;113(5):288-92
pubmed: 11009065
Physiol Rev. 2011 Apr;91(2):461-553
pubmed: 21527731
J Neurotrauma. 2018 Sep 1;35(17):2044-2055
pubmed: 29732941
Nat Rev Neurol. 2010 Apr;6(4):193-201
pubmed: 20234358
J Mol Med (Berl). 2018 Sep;96(9):873-883
pubmed: 30030568
Exp Neurol. 2016 Jan;275 Pt 3:316-327
pubmed: 26342753
J Neuroimmune Pharmacol. 2014 Dec;9(5):716-26
pubmed: 25146376
Int J Legal Med. 2018 Mar;132(2):531-539
pubmed: 29306988
Nat Rev Neurol. 2013 Apr;9(4):201-10
pubmed: 23399646
Int J Legal Med. 2019 Jul;133(4):1107-1114
pubmed: 30073510
Immunity. 2014 Feb 20;40(2):274-88
pubmed: 24530056
Brain Behav Immun. 2012 Nov;26(8):1191-201
pubmed: 22728326
Nat Rev Neurosci. 2011 Jun 15;12(7):388-99
pubmed: 21673720
Immunity. 2013 Mar 21;38(3):555-69
pubmed: 23477737
Neuropathol Appl Neurobiol. 2013 Feb;39(1):3-18
pubmed: 23252647
Int J Legal Med. 2015 Jul;129(4):701-7
pubmed: 25432860
Science. 2005 May 27;308(5726):1314-8
pubmed: 15831717
J Biochem. 2016 May;159(5):491-6
pubmed: 26861995